[
  {
    "ts": "2025-12-23T03:12:46+00:00",
    "headline": "The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why",
    "summary": "In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the company was also removed from the Nasdaq-100 index. At the same time, mixed analyst views now center on how QALSODY’s data, Biogen’s Alzheimer’s drug Leqembi, and its emerging multiple sclerosis pipeline might reshape the company’s future earnings mix as it adapts to index removal. We’ll now...",
    "url": "https://finance.yahoo.com/news/bull-case-biogen-biib-could-031246547.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "03ff38ea-bdc9-3c82-bc32-2d1b11b06719",
      "content": {
        "id": "03ff38ea-bdc9-3c82-bc32-2d1b11b06719",
        "contentType": "STORY",
        "title": "The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 Exit - Learn Why",
        "description": "",
        "summary": "In recent days, Biogen has reported long-term Phase 3 and extension data showing its ALS therapy QALSODY can slow SOD1-ALS progression and, in some cases, help patients regain lost function, while the company was also removed from the Nasdaq-100 index. At the same time, mixed analyst views now center on how QALSODY’s data, Biogen’s Alzheimer’s drug Leqembi, and its emerging multiple sclerosis pipeline might reshape the company’s future earnings mix as it adapts to index removal. We’ll now...",
        "pubDate": "2025-12-23T03:12:46Z",
        "displayTime": "2025-12-23T03:12:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-biogen-biib-could-031246547.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-case-biogen-biib-could-031246547.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]